The "Raynauds
Disease - Pipeline Insight, 2018" drug pipelines has been added
to ResearchAndMarkets.com's offering.
This
report offers a comprehensive insight of the pipeline (under
development) therapeutics scenario and growth prospects across Raynauds
Disease development.
The report provides detailed coverage of
the pipeline landscape for this mechanism of action, equipped with data
from multiple sources with complete pipeline analysis by developmental
stage, associated indications, route of administration and molecule type.
Pipeline
Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.
The report assesses the
active Raynauds Disease pipeline products by developmental stage,
product type, molecule type, and administration route.
Scope
- The report provides a snapshot of the pipeline development for the Raynauds Disease
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Raynauds Disease
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Raynauds Disease
- The report also covers the dormant and discontinued pipeline projects related to the Raynauds Disease
Companies Featured
- Allergan Plc
- Apricus Biosciences Inc
- Covis Pharmaceuticals Inc
- Human Stem Cells Institute
Key Topics Covered
1. Report Introduction
2.
Raynauds Disease Overview
3. Pipeline Therapeutics
4.
Comparative Analysis
5. Products in Clinical Stage
6.
Products in Pre-Clinical and Discovery Stage
7. Therapeutic
Assessment
8. Inactive Products
For more
information about this drug pipelines report visit https://www.researchandmarkets.com/research/4h3hmw/raynauds_disease?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180720005149/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs